Transatlantic health technology investment initiative launched by Meridan Health Ventures, claimed as the first of its kind globally.
Meridian Health Ventures' transatlantic fund is playing a significant role in accelerating the growth of healthtech companies, both domestically and globally. The fund, which was previously known as KHP Ventures, brings together leading health systems, venture investors, institutional investors, and academic centres of excellence from both the US and the UK.
The fund's primary objective is to provide global and domestic growth opportunities for healthtech superscalers. By bridging innovation ecosystems in the U.S. and the UK, it catalyzes cross-border scale for healthtech companies, enabling them to operate and scale effectively on both sides of the Atlantic. This is particularly beneficial for very large, high-growth healthtech firms, as they can expand their reach widely and rapidly.
One of the key areas where the fund is making a substantial impact is within the NHS. By investing in healthtech solutions aligned with NHS needs, the fund is accelerating the development and adoption of cutting-edge technologies that improve healthcare delivery, patient outcomes, and operational efficiency within the NHS.
The fund is also driving technology commercialization by providing capital, strategic guidance, and access to U.S. markets and stakeholders. This fosters sustainable growth for UK startups and scaleups, helping them commercialize innovations emerging from UK health research and development.
Moreover, the fund facilitates public-private collaboration by partnering with public entities like the NHS and private investors across the UK and U.S. This enhances the flow of resources and expertise between governments, health systems, and companies, thus boosting ecosystem capabilities on both continents.
As a result, UK healthtech innovators are strengthening their competitive positioning on the global stage. They are gaining access to U.S. venture capital and broader international networks through the fund, increasing exports and international influence.
Notable healthtech companies in the fund's portfolio include Apian, Doccla, deepc, Patchwork, Tympa Health, iFAST Diagnostics, PocDoc, Phare Health, 52 North, and MediShout. The fund has also backed promising MedTech spin-outs from Cambridge, Oxford, Imperial, King's, and Southampton, with 12 NHS clinical entrepreneurs among its company founders.
Cedars-Sinai Medical Center, Guy's and St Thomas' NHS Foundation Trust, King's College Hospital, University College London Hospitals, Hartford HealthCare, and other leading health systems are backing the fund. The fund's current team includes entrepreneurs, investors, operators, regulators, industry leaders, academics, and clinicians.
The CEO and Co-Founder of Apian, a Meridian Health Ventures portfolio company, started the company within the NHS and has grown alongside partners like Meridian Health Ventures and Trusts like Guy's and St Thomas' NHS Foundation Trust. The fund's portfolio companies, including Zipline and Wing, are focused on delivering care to patients faster.
The NHS is facing challenges in delivering high-quality care against rising demand, increased patient acuity, and pressures on workforce and finance. The transatlantic fund aims to supercharge the growth of promising innovations for direct benefits to the NHS's patients and workforce, as well as the wider UK economy. The fund creates an environment where ambitious founders can scale at pace, both domestically and internationally.
Cedars-Sinai Medical Center sees the fund's mission as deeply aligned with their mission to provide the best care possible for patients around the world. The fund's goal is to create a vibrant ecosystem that fosters innovation, supports growth, and ultimately improves healthcare delivery for patients worldwide.
- The transatlantic Meridian Health Ventures fund, previously known as KHP Ventures, leverages science and technology to facilitate healthtech growth globally and domestically, particularly in the NHS.
- The fund makes strategic investments in companies like Apian, Doccla, and Patchwork, supporting digital health, health-and-wellness, and fitness-and-exercise innovations, while also nurturing MedTech spin-outs from prominent universities.
- By bridging the innovation ecosystems in the U.S. and the UK, the fund is fostering cross-border scale for healthtech companies, attracting finance, and driving investing opportunities in the business sector.
- The fund's mission resonates with leading medical centers like Cedars-Sinai Medical Center, as it aims to develop cutting-edge medical-conditions treatments, enhance operational efficiency, and improve healthcare delivery worldwide.
- In pursuit of these goals, the fund establishes partnerships with entities like the NHS, corporate leaders, and academic centers, thereby fostering public-private collaborations and boosting ecosystem capabilities both in the UK and the US, ultimately benefiting the wider health-and-wellness industry.
